Caxton Associates LP Acquires 34,924 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Caxton Associates LP raised its holdings in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 8.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 466,110 shares of the company’s stock after buying an additional 34,924 shares during the quarter. Caxton Associates LP’s holdings in Allogene Therapeutics were worth $1,086,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Price T Rowe Associates Inc. MD increased its position in shares of Allogene Therapeutics by 76.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 4,177,619 shares of the company’s stock valued at $18,675,000 after purchasing an additional 1,806,147 shares during the period. Affinity Asset Advisors LLC acquired a new stake in shares of Allogene Therapeutics in the fourth quarter valued at $1,284,000. Susquehanna Fundamental Investments LLC bought a new stake in Allogene Therapeutics during the 1st quarter worth about $1,280,000. TD Asset Management Inc increased its position in Allogene Therapeutics by 82.7% in the 2nd quarter. TD Asset Management Inc now owns 799,340 shares of the company’s stock valued at $1,862,000 after acquiring an additional 361,904 shares in the last quarter. Finally, Primecap Management Co. CA raised its stake in shares of Allogene Therapeutics by 4.1% in the second quarter. Primecap Management Co. CA now owns 5,670,226 shares of the company’s stock worth $13,212,000 after acquiring an additional 221,840 shares during the last quarter. 83.63% of the stock is owned by institutional investors.

Allogene Therapeutics Trading Up 3.8 %

NASDAQ:ALLO opened at $2.72 on Friday. Allogene Therapeutics, Inc. has a 1 year low of $2.01 and a 1 year high of $5.78. The stock has a 50-day moving average price of $2.67 and a two-hundred day moving average price of $2.97. The stock has a market cap of $568.78 million, a price-to-earnings ratio of -1.52 and a beta of 0.83.

Allogene Therapeutics (NASDAQ:ALLO) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.03. Allogene Therapeutics had a negative return on equity of 50.24% and a negative net margin of 223,139.98%. Sell-side analysts forecast that Allogene Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on ALLO shares. Canaccord Genuity Group dropped their target price on Allogene Therapeutics from $35.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, August 8th. HC Wainwright reissued a “buy” rating and set a $9.00 price target on shares of Allogene Therapeutics in a research note on Thursday, August 15th. Piper Sandler started coverage on shares of Allogene Therapeutics in a research note on Friday, May 31st. They issued an “overweight” rating and a $11.00 price objective on the stock. Citigroup upped their target price on shares of Allogene Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Finally, Oppenheimer assumed coverage on Allogene Therapeutics in a research report on Thursday, August 8th. They issued an “outperform” rating and a $11.00 price target on the stock. Three analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $9.96.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).